Please use this identifier to cite or link to this item:
https://hdl.handle.net/1959.11/31276
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Watts, Gerald F | en |
dc.contributor.author | Chan, Dick C | en |
dc.contributor.author | Somaratne, Ransi | en |
dc.contributor.author | Wasserman, Scott M | en |
dc.contributor.author | Scott, Rob | en |
dc.contributor.author | Marcovina, Santica M | en |
dc.contributor.author | Barrett, P Hugh R | en |
dc.date.accessioned | 2021-08-11T02:54:59Z | - |
dc.date.available | 2021-08-11T02:54:59Z | - |
dc.date.issued | 2018-07-14 | - |
dc.identifier.citation | European Heart Journal, 39(27), p. 2577-2585 | en |
dc.identifier.issn | 1522-9645 | en |
dc.identifier.issn | 0195-668X | en |
dc.identifier.uri | https://hdl.handle.net/1959.11/31276 | - |
dc.description.abstract | <p><b>Aims</b></p><p> Lipoprotein(a) [Lp(a)], a low-density lipoprotein (LDL) particle covalently bound to apolipoprotein(a) [apo(a)], is a potentially potent heritable risk factor for cardiovascular disease. We investigated the mechanism whereby evolocumab, a monoclonal antibody against proprotein convertase subtilisin-kexin type 9 (PCSK9), lowers Lp(a).</p><p><b>Methods and results</b></p><p> We studied the kinetics of Lp(a) particles in 63 healthy men, with plasma apo(a) concentration >5 nmol/L, participating in an 8-week factorial trial of the effects of evolocumab (420 mg every 2 weeks) and atorvastatin (80 mg daily) on lipoprotein metabolism. Lipoprotein(a)-apo(a) kinetics were studied using intravenous D3-leucine administration, mass spectrometry, and compartmental modelling; Lp(a)-apoB kinetics were also determined in 16 subjects randomly selected from the treatment groups. Evolocumab, but not atorvastatin, significantly decreased the plasma pool size of Lp(a)-apo(a) (−36%, <i>P</i> < 0.001 for main effect). As monotherapy, evolocumab significantly decreased the production of Lp(a)-apo(a) (−36%, <i>P</i> < 0.001). In contrast, in combination with atorvastatin, evolocumab significantly increased the fractional catabolism of Lp(a)-apo(a) (+59%, <i>P</i>< 0.001), but had no effect on the production of Lp(a)-apo(a). There was a highly significant association between the changes in the fractional catabolism of Lp(a)-apo(a) and Lp(a)-apoB in the substudy of 16 subjects (<i>r</i> =0.966, ,<i>P</i> < 0.001). </p><p><b>Conclusions</b></p><p> Evolocumab monotherapy lowered the plasma Lp(a) pool size by decreasing the production of Lp(a) particles. In combination with atorvastatin, evolocumab lowered the plasma Lp(a) pool size by accelerating the catabolism of Lp(a) particles. This dual mechanism may relate to an effect of PCSK9 inhibition on Lp(a)-apo(a) production and to marked up-regulation of LDL receptor activity on Lp(a) holoparticle clearance.</p> | en |
dc.language | en | en |
dc.publisher | Oxford University Press | en |
dc.relation.ispartof | European Heart Journal | en |
dc.title | Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics | en |
dc.type | Journal Article | en |
dc.identifier.doi | 10.1093/eurheartj/ehy122 | en |
dcterms.accessRights | Gold | en |
local.contributor.firstname | Gerald F | en |
local.contributor.firstname | Dick C | en |
local.contributor.firstname | Ransi | en |
local.contributor.firstname | Scott M | en |
local.contributor.firstname | Rob | en |
local.contributor.firstname | Santica M | en |
local.contributor.firstname | P Hugh R | en |
local.profile.school | Faculty of Medicine and Health | en |
local.profile.email | pbarret6@une.edu.au | en |
local.output.category | C1 | en |
local.record.place | au | en |
local.record.institution | University of New England | en |
local.publisher.place | United Kingdom | en |
local.format.startpage | 2577 | en |
local.format.endpage | 2585 | en |
local.identifier.scopusid | 85046624628 | en |
local.peerreviewed | Yes | en |
local.identifier.volume | 39 | en |
local.identifier.issue | 27 | en |
local.access.fulltext | Yes | en |
local.contributor.lastname | Watts | en |
local.contributor.lastname | Chan | en |
local.contributor.lastname | Somaratne | en |
local.contributor.lastname | Wasserman | en |
local.contributor.lastname | Scott | en |
local.contributor.lastname | Marcovina | en |
local.contributor.lastname | Barrett | en |
dc.identifier.staff | une-id:pbarret6 | en |
local.profile.orcid | 0000-0003-3223-6125 | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.profile.role | author | en |
local.identifier.unepublicationid | une:1959.11/31276 | en |
local.date.onlineversion | 2018-03-16 | - |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
dc.identifier.academiclevel | Academic | en |
local.title.maintitle | Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics | en |
local.relation.fundingsourcenote | Amgen Inc | en |
local.output.categorydescription | C1 Refereed Article in a Scholarly Journal | en |
local.search.author | Watts, Gerald F | en |
local.search.author | Chan, Dick C | en |
local.search.author | Somaratne, Ransi | en |
local.search.author | Wasserman, Scott M | en |
local.search.author | Scott, Rob | en |
local.search.author | Marcovina, Santica M | en |
local.search.author | Barrett, P Hugh R | en |
local.uneassociation | No | en |
local.atsiresearch | No | en |
local.sensitive.cultural | No | en |
local.year.available | 2018 | en |
local.year.published | 2018 | en |
local.fileurl.closedpublished | https://rune.une.edu.au/web/retrieve/142efe1d-7987-435e-85e6-d3275ed92c6e | en |
local.subject.for2020 | 320101 Cardiology (incl. cardiovascular diseases) | en |
local.subject.for2020 | 320803 Systems physiology | en |
local.subject.seo2020 | 200105 Treatment of human diseases and conditions | en |
dc.notification.token | 2e49e298-c0b8-4f80-8c77-002a51e0a996 | en |
Appears in Collections: | Journal Article |
Files in This Item:
File | Size | Format |
---|
SCOPUSTM
Citations
113
checked on Jun 8, 2024
Page view(s)
884
checked on Jul 23, 2023
Download(s)
2
checked on Jul 23, 2023
Items in Research UNE are protected by copyright, with all rights reserved, unless otherwise indicated.